Lexington, KY, United States of America

John Hayslip

This inventor holds 1 USPTO granted patent and 4 published patent applications. Top assignees: Abbvie Deutschland Gmbh and Co Kg, Abbvie Inc.. Active years: 2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: John Hayslip. Retrieved from https://idiyas.com/inventor/john-hayslip

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2022

Loading Chart...
1 patent (USPTO):Explore Patents

Title: John Hayslip: Innovator in Myelofibrosis Treatment

Introduction

John Hayslip is a notable inventor based in Lexington, KY (US). He has made significant contributions to the field of medicine, particularly in the treatment of myelofibrosis and related disorders. His innovative approach has led to the development of a unique patent that addresses critical health issues.

Latest Patents

Hayslip holds a patent for "Dosing regimens for use in treating myelofibrosis and MPN-related disorders with navitoclax." This invention describes methods for treating a human subject with myelofibrosis or an MPN-related disorder by administering navitoclax, optionally in combination with ruxolitinib. This patent represents a significant advancement in therapeutic strategies for these conditions, showcasing Hayslip's commitment to improving patient outcomes. He has 1 patent to his name.

Career Highlights

Throughout his career, Hayslip has worked with prominent companies in the pharmaceutical industry. Notably, he has been associated with AbbVie Inc. and Abb Vie Deutschland GmbH & Co. KG. His experience in these organizations has provided him with valuable insights into drug development and patient care.

Collaborations

Hayslip has collaborated with several professionals in his field, including Leanne M. Holes and Sven Mensing. These partnerships have likely contributed to the success of his innovations and the advancement of treatment methodologies.

Conclusion

John Hayslip's work in developing treatment regimens for myelofibrosis and MPN-related disorders highlights his dedication to medical innovation. His contributions are paving the way for improved therapies and better patient care in the future.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…